Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Lara Gechijian(Jnana Therapeutics (United States)), James E. Bradner(Harvard University), Jennifer A. Perry(Dana-Farber Cancer Institute), Joshiawa Paulk(Dana-Farber Cancer Institute), Nathanael S. Gray(Stanford University), Matthew A. Lawlor(Dana-Farber Cancer Institute), Jaime M. Reyes(Dana-Farber Cancer Institute), Georg E. Winter(Austrian Academy of Sciences), Michael A. Erb(Scripps Research Institute), Hyuk‐Soo Seo(Dana-Farber Cancer Institute), Jun Qi, Mousheng Xu(Dana-Farber Cancer Institute), Dennis L. Buckley(Dana-Farber Cancer Institute), Nicholas Kwiatkowski(Harvard University), Christopher J. Ott(Broad Institute), Sirano Dhe‐Paganon(Neuroendocrine Tumor Research Foundation), Thomas G. Scott(Dana-Farber Cancer Institute)
Cited by 229
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k
Crystal Structure of the Tyrosine Phosphatase SHP-2
|Cell|1998|1k